Beta-2-microglobulin amyloidosis: Past, present and future

Ignacio Portales Castillo, Jerry Yee, Hiroshi Tanaka, Andrew Z. Fenves
2020 Kidney360  
Almost half a century has elapsed since the first description of dialysis-related amyloidosis (DRA) a disorder caused by excessive accumulation of beta-2 microglobulin (B2M). Within that period, substantial advances in renal replacement therapy (RRT) occurred. These improvements have led to a decrease in the incidence of DRA. In many countries, DRA is considered a "disappearing act" or complication. Although the prevalence of patients living with RRT increases, not all will have access to
more » ... ave access to kidney transplantation. Consequently, the number of patients requiring interventions for treatment of DRA is postulated to increase. This postulate has been borne out in Japan where the number of end-stage kidney disease (ESKD) patients requiring surgery for carpal tunnel continues to increase. Clinicians treating patients with ESKD have treatment options to improve B2M clearance, however, there is a need to identify ways to translate improved B2M clearance into improved quality of life for patients undergoing long-term dialysis.
doi:10.34067/kid.0004922020 fatcat:6ta6zcds7fgwjnybxz72xg6uau